We have investigated whether an alternating induction chemotherapy regimen of PVB BEP is superior to BEP in patients with poor-prognosis testicular non-seminoma. A total of 234 eligible patients were randomised to receive an alternating schedule of PVB/BEP for a total of four cycles or four cycles of BEP. Poor prognosis was defined as any of the following: lymph node metastases larger than 5 cm, lung metastases more than four in number or larger than 2 cm, haematogenic spread outside the lungs, such as in liver and bone, human chorionic gonadotrophin> 10 000 IU I -' or alphafetoprotein> 1000 IU 1-'. The complete response (CR) rates to PVB/BEP and BEP were similar, 76% and 72% respectively (P = 0.58). In addition, there was no significant difference in relapse rate, disease-free and overall survival at an average follow-up of 6 years. The 5-year progression-free and survival rates in both treatment groups were approximatley 80%. The PVBIBEP regime was more toxic with regard to bone marrow function; the frequencies of leucocytes below 1000 gIl-', leucocytopenic fever and platelets below 25000 gi1', throughout four cycles were 28% vs 5% (P< 0.001), 16% vs 5% (P= 0.006), and 10% vs 1% (P= 0.001) respectively. Neuropathy also occurred more often in the PVB,BEP arm: 47% vs 25% (P=0.001). This study shows that an alternating regimen of PVB'BEP is not superior to BEP and that it is more myelo-and neurotoxic.
Cisplatin combination chemotherapy has increased the longterm survival rates of patients with disseminated testicular non-seminoma from 10% to approximately 70% (Einhorn, 1981; Stoter et al., 1989) . Variables associated with a poor prognosis include extent of metastases and serum levels of a-subunit of human chorionic gonadotrophin (HCG) above 10 000 IU 1-' and/or alphafetoprotein (AFP) above 1000 IU 1-1 (Medical Research Council, 1985; Bosl et al., 1983; Birch et al., 1986; Stoter et al., 1987) . Several studies have shown that complete (CR) rates fall by 30-50% in the presence of one or more poor-prognosis factors (Bajorin et al., 1988; Mead et al., 1992) .
Etoposide has been shown to be active against cisplatinresistant germ cell tumours, indicating non-cross-resistance (Williams et al., 1980; Bosl et al., 1985) . Moreover, the combination of cisplatin, etoposide and bleomycin (BEP) has greater anti-tumour activity in poor-prognosis patients than the combination of cisplatin, vinblastine and bleomycin (PVB) (Williams et al., 1987) . To improve the results of induction chemotherapy in patients with poor-prognosis criteria, both the introduction of new active agents and the concept of alternating chemotherapy combinations could be exploited (Goldie et al., 1982; Goldie and Coldman, 1984) . Therefore, the Genitourinary Group of the European Organization for Research and Treatment of Cancer (EORTC) decided to perform a randomised study of four cycles of induction chemotherapy comparing BEP as the standard regimen with alternating cycles of PVB and BEP in poor-prognosis patients. The definition of poor prognosis was derived from the preceding EORTC study in which PBV-treated patients with lymph node metastases > 5 cm or lung metastases > 2 cm achieved a CR rate of only 56% as compared with 88% in patients with less extensive metastases (Stoter et al., 1986) .
Materials and methods
Patients were eligible for the study if they had metastatic testicular non-seminoma with any of the following characteristics: lymph node metastases > 5 cm, lung metastases >4 in number or > 2 cm, haematogenic spread outside the lungs such as in liver or bone, HCG> 10 000 IU 1-' or AFP > 1000 IU 1-'. These cut-off levels of serum markers were based on prognostic factors analyses of EORTC (Stoter et al., 1986) and MRC (Medical Research Council, 1985 Rising tumour markers or an increase in tumour volume was considered as an endpoint indicating progression of disease. Response rates to the treatment regimens were compared by using the standard chi-square test for contingency tables. For comparison of toxicity, a chi-square test for linear trend was used. Time to progression and duration of survival curves were computed using the Kaplan-Meier product limit method and were compared using the log-rani test (Breslow, 1984 and 76%, respectively (P = 0.58) (Table I) . When the inevaluable patients are included in the response analysis as treatment failures, the CR rates were again not statistically different 64% on BEP and 67% on PVB/BEP (P = 0.65). After an average follow-up of 6 years (maximum 10 years) the relapse rates from CR were 16% on BEP and 12% on PVB/BEP (P = 0.50).
Time to progression and survival There were no significant differences in time to progression (P = 0.27) or duration of survival (P = 0.32) between the treatment groups. Figure 1 gives the duration of survival by treatment group for all 234 eligible patients. The 5 year progression-free and survival rates in both treatment groups are approximately 80%. When the log-rank survival analysis is restricted to the group of complete responders, the 5 year survival is 92%. Nine complete responders have died on BEP and six on PVB/BEP, thus there is again no significant difference between the two groups (P = 0.41). 
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